Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,679,472
  • Shares Outstanding, K 2,504,140
  • Annual Sales, $ 42,147 M
  • Annual Income, $ 3,256 M
  • 60-Month Beta 0.55
  • Price/Sales 2.98
  • Price/Cash Flow 7.38
  • Price/Book 1.76
Trade SNY with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.80
  • Number of Estimates 2
  • High Estimate 0.86
  • Low Estimate 0.73
  • Prior Year 0.74
  • Growth Rate Est. (year over year) +8.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.88 +5.35%
on 12/21/20
49.69 -0.60%
on 01/15/21
+3.10 (+6.71%)
since 12/15/20
3-Month
44.76 +10.34%
on 10/30/20
51.62 -4.32%
on 11/11/20
-0.57 (-1.14%)
since 10/15/20
52-Week
37.62 +31.29%
on 03/23/20
55.00 -10.20%
on 07/16/20
-1.86 (-3.63%)
since 01/15/20

Most Recent Stories

More News
The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group

The Zacks Analyst Blog Highlights: Apple, Mastercard, Sanofi, Comcast and Altria Group

CMCSA : 48.69 (-1.80%)
MO : 41.20 (+0.22%)
SNY : 49.39 (+0.73%)
AAPL : 127.14 (-1.37%)
MA : 323.26 (-1.12%)
Top Stock Reports for Apple, Mastercard & Sanofi

Top Stock Reports for Apple, Mastercard & Sanofi

SNY : 49.39 (+0.73%)
MO : 41.20 (+0.22%)
MA : 323.26 (-1.12%)
CMCSA : 48.69 (-1.80%)
BP : 24.26 (-4.75%)
AAPL : 127.14 (-1.37%)
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

SNY : 49.39 (+0.73%)
BMY : 66.54 (+0.79%)
HALO : 47.43 (+0.81%)
LXRX : 6.87 (-14.66%)
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

SNY : 49.39 (+0.73%)
RHHBY : 44.5600 (+1.39%)
PFE : 36.70 (-0.14%)
MRK : 83.38 (+1.47%)
LLY : 190.77 (+2.19%)
GSK : 38.47 (+0.81%)
NVS : 95.63 (+1.07%)
Esperion (ESPR) Reports Q4 Preliminary Results, Stock Down

Esperion (ESPR) reports fourth-quarter preliminary results and provides guidance for operating expense in 2021. The company in-licenses oral PCSK9 inhibitor program.

SNY : 49.39 (+0.73%)
MRK : 83.38 (+1.47%)
AMGN : 245.49 (+1.58%)
ESPR : 25.55 (-4.49%)
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor

MISGAV, , /PRNewswire/ --  ("Biond" or the "Company"), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics,...

SNYNF : 98.6000 (-0.94%)
SAN : 3.29 (-3.80%)
SNY : 49.39 (+0.73%)
Sanofi (SNY) to Acquire Kymab to Boost Immunology Presence

Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.

ALXN : 156.70 (+0.03%)
REGN : 517.93 (unch)
SNY : 49.39 (+0.73%)
MRK : 83.38 (+1.47%)
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines

--HIV vaccine program to accelerate human validation of novel vaccination strategies

MRNA : 129.65 (-0.05%)
AMGN : 245.49 (+1.58%)
SNY : 49.39 (+0.73%)
PFE : 36.70 (-0.14%)
GSK : 38.47 (+0.81%)
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Corinne Le Goff, Pharm.D., MBA, will join Moderna as Chief Commercial...

MRNA : 129.65 (-0.05%)
AMGN : 245.49 (+1.58%)
SNY : 49.39 (+0.73%)
PFE : 36.70 (-0.14%)
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study

Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.

SNY : 49.39 (+0.73%)
BMY : 66.54 (+0.79%)
HALO : 47.43 (+0.81%)
LXRX : 6.87 (-14.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

3rd Resistance Point 50.74
2nd Resistance Point 50.22
1st Resistance Point 49.80
Last Price 49.39
1st Support Level 48.86
2nd Support Level 48.34
3rd Support Level 47.92

See More

52-Week High 55.00
Last Price 49.39
Fibonacci 61.8% 48.36
Fibonacci 50% 46.31
Fibonacci 38.2% 44.26
52-Week Low 37.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar